MicroSintesis, Inc.
Business Description
MicroSintesis is a Microbiome Biotech Company with its research center based in PEI, Canada. We develop microbiome feed technologies and therapies to prevent and treat animal bacteria infections. Through our innovative research program and patented technology, we seek to understand how bacteria communication (Quorum Sensing) can be used to change pathogen behaviors and restore natural microbiome function, in the face of disease challenges.
Our purpose is to change the way we fight disease, and our vision is to be a leading animal microbiome technology Company. Using our unique bioassay platform, we have developed and are commercializing, two distinct microbiome feed products targeting two important dysbiosis-causing gram-negative and gram-positive pathogens. We are now expanding that program to critically important pathogens for companion animals and dairy cows.
To date, the Company holds over 65 patents across 5 technology platforms and has published its scientific work in prestigious publications such as Nature and Avian Pathology. Our research activities span both a mechanistic understanding of Quorum Sensing Inhibition as well as applied research. We work across 4 main research areas: Molecular and cell biology; Analytical Chemistry and Protein Purification; Microbiology and Fermentation; and Clinical/In-vivo lab research and Microbiome sampling and analysis.
Over the past 4 years, the Company has established a number or important research, academic and technical collaborations as well as commercial partnerships. Many of our research collaborations are with some of the leading experts within their technical fields. Our partnership goals are to advance the world’s understanding of the role of bacteria communication in microbiome diseases and function. To support this, we have performed over 12 clinical trials in the past 3 years, and we expect to test our technology in 3 new disease target models in the next twelve months.